Αποτελέσματα Αναζήτησης
19 Ιουν 2023 · •The addition of pembrolizumab to taxane-platinum–based chemotherapy followed by an anthracycline significantly increased pathologic complete response (pCR) rates and improved event-free survival in early-stage high-risk TNBC.
15 Φεβ 2023 · The standard treatment for early TNBC is neoadjuvant chemotherapy, followed by surgery. Based on the survival benefit of the KEYNOTE-522 trial, a combination of pembrolizumab with anthracycline, taxane, and carboplatin is currently the treatment of choice.
29 Μαΐ 2024 · TNBC was defined as per ASCO-CAP guidelines as ER≤1%, PR≤1% and negative HER 2 (0, 1+ by immunohistochemistry, or 2+ ISH negative). Outcomes of interest included event free survival (EFS), overall survival (OS), and pathologic complete response (pCR).
29 Μαΐ 2020 · In the adaptive neoadjuvant phase II I-SPY 2 trial, the AKT inhibitor MK-2206 plus standard neoadjuvant chemotherapy of weekly paclitaxel followed by AC achieved an estimated pCR rate of 40% when compared with 22% from chemotherapy alone in the TNBC subgroup . These results support further evaluation of AKT inhibition + paclitaxel and AC ...
TNBC presents a significant treatment challenge due to its aggressive nature and limited targeted therapy options 1, 2.Systemic multiagent chemotherapy improves long-term outcomes and is recommended for stage I–III TNBC disease, with most patients in the current era being treated with neoadjuvant chemotherapy 3.Anthracyclines and cyclophosphamide (AC) have typically constituted the ...
9 Νοε 2021 · Tumour heterogeneity and a long-standing paucity of effective therapies other than chemotherapy have contributed to triple-negative breast cancer (TNBC) being the subtype with the least...
2 Φεβ 2022 · The results suggested that 4 cycles of AC followed by weekly paclitaxel (AC*4-wP*12) may be the preferred choice for adjuvant chemotherapy of TNBC patients.
